551O - Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER

Background

HER2 is an actionable biomarker for mCRC, though the impact of concomitant genomic alterations is unknown. On the basis of the MOUNTAINEER study, TUC + Tras was approved by the FDA for use in pts with chemo-refractory HER2+, RAS-WT mCRC. Here we present the impact of concomitant baseline genomic alterations on the clinical activity of TUC + Tras.

Methods

MOUNTAINEER enrolled pts w/ locally assessed HER2+ mCRC by tissue immunohistochemistry (IHC), in situ hybridization (ISH), and/or next-generation sequencing (NGS). Baseline tissue and blood samples were retrospectively analyzed by IHC/FISH, PGDx tissue NGS and Guardant 360 blood NGS. cORRs (proportion of pts w/ CR or PR per RECIST v1.1 by BICR) and DoR were calculated for selected genomic alterations (SNVs and CNVs) occurring in ≥5 pts treated with TUC + Tras. This analysis was descriptive; no statistical comparisons were made.

Results

From 84 pts treated with TUC+Tras, 65 samples were available for FISH testing. cORR was numerically higher w/ greater HER2 amplification as measured by either HER2/CEP17 ratio (>5, n=50: cORR [95%CI] = 44.0% [30.0, 58.7]; ≤5, n=15: cORR [95%CI] = 26.7% [7.8, 55.1]) or HER2 copy number (>9.45, n=57: cORR [95%CI] = 42.1% [29.1, 55.9]; ≤9.45, n=8: cORR [95%CI] = 25.0% [3.2, 65.1]). NGS testing of tissue (n=45) and blood (n=66) samples from pts w/ a central HER2+ test result identified concomitant mutations and/or genomic amplifications in key genes including ERBB2, PIK3CA, APC, and TP53. In these pts, cORR and DOR were generally similar to those observed overall (Table).

Conclusions

This exploratory analysis of the MOUNTAINEER trial found generally consistent clinical efficacy of TUC + Tras to the primary analysis across subsets of pts w/ HER2+ RAS-WT mCRC and other clinically relevant genomic alterations.

Table: 551O

*cORR and DOR were not calculated for sample sizes <5.

Clinical trial identification

EudraCT Number 2020-000540-60.

Editorial acknowledgement

The authors thank Sarah Canestaro, MS, of Populus Group, Troy, MI, supported by Seagen Inc. for providing medical writing and editorial support in accordance with Good Publication Practice guidelines.

Legal entity responsible for the study

Seagen Inc.

Funding

This study was sponsored by Seagen Inc., Bothell, WA, USA, in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Disclosure

J.H. Strickler: Financial Interests, Personal, Advisory Board: SeaGen, AstraZeneca, Amgen, Pfizer, Bayer, AbbVie, Natera, Viatris, Inivata, Silverback Therapeutics; Financial Interests, Personal, Other, Consulting: Mereo, GSK, Pionyr Immunotherapeutics; Financial Interests, Institutional, Invited Speaker: SeaGen, Roche Genentech, AbbVie, AstraZeneca, Amgen, Astar D3, Sanofi, Curegenix, Nektar, Leap Therapeutics, Daiichi Sankyo, Erasca, Gossamer Bio, Silverback Therapeutics. A. Cercek: Financial Interests, Personal, Advisory Board: Bayer, GSK, Janssen, Merck, Seagen, Pfizer; Financial Interests, Personal, Stocks/Shares: Haystack; Financial Interests, Personal, Royalties, Pending patent neoadjuvant PD1 blocked in mismatch repair deficient solid tumors: Memorial Sloan Kettering; Financial Interests, Personal, Royalties, Pending patent for HAI FUDR in DPD metastatic colorectal cancer: Memorial Sloan Kettering Cancer Center; Financial Interests, Institutional, Invited Speaker, Clinical trial funding: Seattle Genetics; Financial Interests, Institutional, Invited Speaker, Clinical trial: GSK. K. Ng: Financial Interests, Personal, Advisory Board, Was also a paid speaker as well for colorectal cancer awareness in March 2022: Bayer; Financial Interests, Personal, Advisory Board: Bicara Therapeutics, GSK, Pfizer, Redesign Health; Financial Interests, Institutional, Funding: Evergrande Group; Financial Interests, Institutional, Research Grant: Janssen, Revolution Medicines; Non-Financial Interests, Leadership Role, Chair of Scientific Program Committee for 2023 Annual Meeting: ASCO; Non-Financial Interests, ,Advisory Role: Colorectal Cancer Alliance, Colon Cancer Foundation, Fight CRC, Prevent Cancer Foundation; Non-Financial Interests, Principal Investigator: Alliance for Clinical Trials in Oncology; Non-Financial Interests, Institutional, Product Samples, Provides product for an NCI cooperative group phase III trial for which I am National Study Chair: Pharmavite. S. Siena: Financial Interests, Personal, Advisory Board, Advisory Board Member: Agenus, AstraZeneca, Bristol Myers Squibb, Checkmab, Daiichi Sankyo, GSK, Novartis, Seagen, T-One-Therapeutics. T. André: Financial Interests, Personal, Advisory Board, Advosiry Board on February 12, 2021: Astellas Pharma; Financial Interests, Personal, Advisory Board, Advisory Board on February 2021: Kaleido Biosciences; Financial Interests, Personal, Invited Speaker, and advisory board 2021: Amgen; Financial Interests, Personal, Invited Speaker, Invited speaker in a symposuim december 2020: AstraZeneca; Financial Interests, Personal, Advisory Board, and consultant fees and consultant contract 2021 and 2022: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board, Advisory board in Janaury 2020 : Clovis; Financial Interests, Personal, Advisory Board, Advisory board in January 2020: Gritstone Oncology; Financial Interests, Personal, Advisory Board, Advisory board 2020: Haliodx; Financial Interests, Personal, Advisory Board, and consultant fees/consultant contract and invited speaker: MSD Oncology; Financial Interests, Personal, Invited Speaker, and other: Pierre Fabre; Financial Interests, Personal, Invited Speaker, in an symposuim in 2020: Roche; Financial Interests, Personal, Invited Speaker, in a meeting in 2019: Ventana; Financial Interests, Personal, Invited Speaker, In a educational meeting in 2019: Sanofi; Financial Interests, Personal, Advisory Board, in a symposuim in 2020: Servier; Financial Interests, Personal, Expert Testimony, Consultant with personnal fees and invited speaker: Servier; Financial Interests, Personal, Advisory Board, in 2019: GSK; Financial Interests, Personal, Invited Speaker, in 2020 and 2021: GSK; Financial Interests, Personal, Invited Speaker, Virtual symposuimLecture: 1 MSI-H CRC: Implementation of Immunotherapy in clinical practice (30 minutes) – (this will be pre-recorded) Q&A – Live Q&A – (10 minutes) (on July 2, 2021): MSD Oncology; Financial Interests, Personal, Invited Speaker, June 2022 : Sanofi; Financial Interests, Personal, Advisory Board, Contract 2021, 2022, 2023: Merck & Co., Inc; Financial Interests, Personal, Advisory Board, Contrat 2019, 2020, 2021, 2022: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board, Contract 2021: Gritstone Oncologie; Financial Interests, Personal, Invited Speaker, June 2022 and June 2023 during ESMO GI meeting: Seagen; Financial Interests, Personal, Invited Speaker, Contract of consulting 2021 and 2022 and 2023: MSD Oncology; Financial Interests, Personal, Advisory Board, September 2022 : GSK, Seagen; Financial Interests, Personal, Invited Speaker, Contract of consulting 2022 and 2023: GSK; Financial Interests, Personal, Invited Speaker, Contract of consulting 2022: Nordic Pharma; Financial Interests, Personal, Invited Speaker, October 2022: Merck Serono; Financial Interests, Personal, Other, Educationnal in 2022: Roche; Financial Interests, Personal, Other, Contract of consulting 2020, 2021, 2022,2023: Servier; Financial Interests, Personal, Advisory Board, 2023: Aptide Health, Glilead; Financial Interests, Institutional, Other, Investigator and scientific committee president: Gercor Academic group; Financial Interests, Institutional, Invited Speaker, PI Garnet study: GSK; Financial Interests, Institutional, Invited Speaker, Keynote 164 and 171 and 811 and C08: MSD; Financial Interests, Institutional, Invited Speaker, Bristol Myers Squibb CA209-8HW, Bristol Myers Squibb CA209-142, Bristol Myers Squibb CA209-577: Bristol Myers Squibb; Financial Interests, Institutional, Invited Speaker, SPOTLIGHT study: Astellas; Financial Interests, Personal, Invited Speaker, and International PI (trial chair Solstice study): Servier; Financial Interests, Personal, Invited Speaker, MOUNTAINEER and MOUNTAINEER-03 study (PI for France) 2022, 2023: Seagen; Non-Financial Interests, Invited Speaker, Investigator: Gercor group; Non-Financial Interests, Invited Speaker, President since October 2022: ARCAD Foundation . E. Van Cutsem: Financial Interests, Personal, Advisory Board: AbbVie, ALX, Amgen, Array, Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GSK, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seattle Genetics, Servier, Takeda, Terumo, Taiho, Zymeworks; Financial Interests, Institutional, Research Grant: Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier. C. Wu: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Array Biopharma, Pfizer, Exelexis, Seagen, Natera; Financial Interests, Personal, Invited Speaker: PrecisCA; Financial Interests, Institutional, Invited Speaker: Pfizer, Hutchmed, Xilis; Non-Financial Interests, Advisory Role, Safety monitoring committee: Seagen. A.S. Paulson: Financial Interests, Personal, Invited Speaker, Medical education, non-branded, industry sponsored: Ideo Oncology; Financial Interests, Personal, Advisory Board: Amgen, Bristol Myers Squibb, Eisai, Ipsen, Incyte, Exelixis, AAA, Pfizer, QED, Lilly, Mirati, Hutchinson, Astellas; Financial Interests, Personal, Stocks/Shares: Alexion, Actinium, Aptose; Financial Interests, Invited Speaker: Ipsen, Hutchinson, Bristol Myers Squibb, Exelixis, Hutchinson med, Taiho, Lilly, AstraZeneca, Incyte, Seattle Genetics, Deciphera, Tempus, Zentalis, G1 therapeutics, Merck, Camurus, Novartis, Surface, Relay Therapeutics; Financial Interests, Institutional, Invited Speaker: Mirati, Bayer. J. Hubbard: Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Institutional, Advisory Board: Incyte, Bayer, BeiGene; Financial Interests, Institutional, Invited Speaker: Boston Biomedical, Senhwa Biosciences, Bayer, Merck, Taiho Pharmaceutical, TreoBio, Hutchison MediPharma, Seattle Genetics, Tovogene, Trioncology, Incyte, Pionyr, G1 Therapeutics, Effector Therapeutics, Roche. A.L. Coveler: Financial Interests, Institutional, Invited Speaker: Seagen, AbGenomics, Novocure, Amgen, Actuate Therapeutics, Surface Oncology, Nucana, Nextrast. C. Fountzilas: Financial Interests, Institutional, Research Grant: Pfizer Inc, Taiho Oncology, Merck Sharp & Dohme Corp., National Comprehensive Cancer Network; Financial Interests, Institutional, Invited Speaker: Seattle Genetics, Inc., TransThera Biosciences, AstraZeneca, Aravive, Inc., Merck Sharp & Dohme Corp., Puma Biotechnology, Kadmon, Astellas Pharma, Pfizer Inc, Dragonfly Therapeutics, MedImmune, LLC., Hoosier Cancer Research Network, Incyte Corporation, Rafael Pharmaceuticals, Kinex Phamaceuticals, Syndax Pharmaceuticals, SWOG, National Cancer Institute, Erythech Pharma, Lilly, Corcept Therapeutics, Ipsen, CG Pharmaceuticals, Biomea Fusion, Bellicum, Amgen Inc.; Non-Financial Interests, Institutional, Other, Principal Investigator on upcoming clinical trial evaluating biomarker for treatment selection in pancreatic cancer: Valar Labs. A. Kardosh: Financial Interests, Personal, Advisory Board: Exelixis, Eisai, Astellas Pharma, AstraZeneca, Genentech; Financial Interests, Research Grant: Natera Inc. P.M. Kasi: Financial Interests, Personal, Advisory Board, Consultancy/Advisory Board: Foundation Medicine, Natera Oncology, AstraZeneca, Merck MSD, Tempus, Bayer, Lilly, Delicath Systems, QED Therapeutics, Servier, Taiho Oncology, Exact Sciences, Eisai; Financial Interests, Institutional, Advisory Board, Consultancy/Advisory Board: Taiho, Ipsen; Financial Interests, Institutional, Funding, Investigator initiated trial cooperative group PI trial support and funding: Tersera; Financial Interests, Institutional, Funding, Investigator initiated trial trial support and funding: Boston Scientific. H.J. Lenz: Financial Interests, Personal, Advisory Board, Advisory Role and Lectures: Bayer; Financial Interests, Personal, Advisory Board, Advisory Role and Lectures: Merck; Financial Interests, Personal, Advisory Board, Advisory Role and lecture: Roche; Financial Interests, Personal, Advisory Board: Jazz Pharmaceuticals, oncocyte, Orion, Astellas, Bristol Myers Squibb; Financial Interests, Personal, Advisory Board, Scientific Advisory Board: 3T Biosscience; Financial Interests, Personal, Advisory Board, Advisory Board: Fulgent, G1 Therapeutics, BioNtech; Financial Interests, Personal, Advisory Board, advisory board: Cardiff; Financial Interests, Personal, Stocks/Shares, Advisory Board: Fulgent. K.K. Ciombor: Financial Interests, Personal, Advisory Board: Pfizer, Merck, Lilly/Loxo, Seagen, Replimune, Personalis, Incyte; Financial Interests, Institutional, Invited Speaker: Genentech, Merck, Incyte, Seagen, Bristol Myers Squibb, Nucana, Daiichi Sankyo, Array. M.E. Elez Fernandez: Financial Interests, Personal, Advisory Board: Hoffman La Roche, Servier, Amgen, Merck Serono, Sanofi, Bayer, Pierre Fabre, MSD; Financial Interests, Personal, Invited Speaker: Organon, Novartis; Financial Interests, Personal, Other, Educational training: Seagen International GmbH; Financial Interests, Institutional, Funding: Hoffmann-La Roche Ltd, Sanofi Aventis Recherche & Développement, Amgen Inc., Boehringer Ingelheim, Novartis Farmacéutica SA, Bristol Myers Squibb International Corporation, BeiGene, HalioDX SAS, Janssen-Cilag SA, Merck Health KGAA, Merck Sharp & Dohme de España SA, PharmaMar SA, Servier, Taiho Pharma USA Inc, Hutchison MediPharma International, Menarini, Merus NV, Pfizer, Mirati, Array Biopharma Inc, AstraZeneca Pharmaceuticals LP, Celgene International SARL, Debiopharm International SA, Genentech Inc, MedImmune; Non-Financial Interests, Other, Coordinator of the SEOM +MIR Section of Residents and Young Assistants: Sociedad Española de Oncología Médica (SEOM); Non-Financial Interests, Other, Speaker of the ESMO Academy: European Society for Medical Oncology (ESMO); Non-Financial Interests, Other, Volunteer member of the ASCO Annual Meeting Scientific Program Committee: Developmental Therapeutics – Immunotherapy: American Society of Clinical Oncology (ASCO); Other, Travel, accommodations, expenses.: Roche, Merck Serono, Sanofi, Amgen, Array BioPharma, Servier, Bristol Myers Squibb. M. Stecher: Financial Interests, Personal, Full or part-time Employment: Seagen; Financial Interests, Personal, Stocks/Shares: Seagen. P. Cronin: Financial Interests, Institutional, Full or part-time Employment: Seagen; Financial Interests, Institutional, Stocks/Shares: Seagen. M. Bieda: Financial Interests, Institutional, Full or part-time Employment, I am an employee of Seagen: Seagen; Financial Interests, Personal, Stocks/Shares, I own stock and stock options in Seagen and have those promised for future: Seagen. T. Bekaii-Saab: Financial Interests, Institutional, Advisory Board: Bayer, Pfizer, Incyte, Ipsen, Seattle Genetics, Genentech, Merck KGA, Merus, Eisai, Servier; Financial Interests, Institutional, Other, DSMB: Merck; Financial Interests, Personal, Advisory Board: AbbVie, Boehringer Ingelheim, Janssen, AstraZeneca, Daiichi Sankyo, Natera, Celularity, Exact Science, Sobi, BeiGene, Xilis, Foundation Medicine, Stemline, Blueprint, Celularity, Caladrius, GSK, Deciphera, Zai Labs, Illumina, Sanofi; Financial Interests, Personal, Other, DSMB: AstraZeneca, Exelixis, The Valley Hospital, Fibrogen; Financial Interests, Personal, Other, DSMC: PanCAN; Financial Interests, Personal, Royalties, WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene: Imugene; Financial Interests, Personal, Royalties, WO/2019/055687: Methods And Compositions For The Treatment Of Cancer Cachexia – Licensed to Recursion: Recursion; Financial Interests, Institutional, Research Grant: Agios, Arys, Bayer, Amgen, Ipsen, Clovis, Pfizer, Celgene, Novartis, Arcus, Atreca, Mirati, Merus, Abgenomics, Bristol Myers Squibb; Financial Interests, Institutional, Invited Speaker: Boston Biomedical, Incyte, Seattle Genetics; Non-Financial Interests, Advisory Role: Imugene, Sun Biopharma.